Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment Conference

Rhea-AI Summary

Cassava Sciences, a clinical-stage biotech company focused on Alzheimer’s disease, will present a corporate overview at the H.C. Wainwright’s 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. ET. The presentation will be available via a live webcast, and a replay will be accessible for 90 days afterwards on their website. Alzheimer’s affects approximately 5.8 million people in the U.S., and the number is expected to rise significantly, highlighting the increasing burden of this condition.

AUSTIN, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22^nd Annual Global Investment Conference.

Event details follow:
Date:	Tuesday, September 15th
Time:	2:30 p.m. Eastern Time
Webcast:	https://www.CassavaSciences.com/company-presentations

Cassava Sciences’ virtual public presentation can be followed live via webcast.  It will also be available for replay for 90 days following the conference on CassavaSciences.com in the ‘Investors’ section.

About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. In the U.S. alone, approximately 5.8 million people are currently living with Alzheimer’s disease, and approximately 487,000 people age 65 or older developed Alzheimer’s in 2019.¹ The number of people living with Alzheimer’s disease is expected to grow dramatically in the years ahead, resulting in a growing social and economic burden.²

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and   develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third-party.

For More Information Contact:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
eschoen@CassavaSciences.com
(512) 501-2450

---

^{1, 2} Source: Alzheimer’s Association. 2019 Alzheimer’s Disease Facts and Figures. Available online at: https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf 

FAQ

What is the date of Cassava Sciences' presentation at the H.C. Wainwright conference?

Cassava Sciences will present on September 15, 2020.

What time is the Cassava Sciences presentation at the investment conference?

The presentation is scheduled for 2:30 p.m. Eastern Time.

Where can I watch the Cassava Sciences presentation?

The presentation will be available via a live webcast on Cassava Sciences' website.

How long will the webcast of the Cassava Sciences presentation be available?

The webcast will be available for replay for 90 days after the conference.

How many people are affected by Alzheimer’s disease in the U.S.?

Approximately 5.8 million people are currently living with Alzheimer’s disease in the U.S.